Famitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Advanced or Metastatic TNBC.
Clinical trial NCT05760378 · RECRUITING
Trial details
- NCT number
- NCT05760378
- Sponsor
- Fudan University
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2023-03-17
- Primary completion
- 2025-01-01
- Enrollment
- 223
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.